Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the response rate of treatment with two
cycles of cisplatin and docetaxel chemotherapy prior to surgery (neoadjuvant) for early stage
non-small cell lung cancer (NSCLC). Secondary objectives of this study include assessment of
radiographic response rate by computed tomography (CT) scanning, overall survival, time to
progression, rate of complete surgical removal, and adverse reactions. In addition, this
study will test whether positron emission tomography (PET) imaging can predict a tumor
response. Patients who have a response to chemotherapy may receive 2 additional cycles after
recovering from surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Providence Health & Services
Collaborators:
Providence Cancer Center, Earle A. Chiles Research Institute Sanofi